Completed PHASE1/PHASE2 INTERVENTIONAL NCT00181506

HI-CHART:Feasibility of High-Dose Accelerated Conformal Radiotherapy

HI-CHART: A Phase I/II Study on the Feasibility of High-Dose Accelerated Conformal Radiotherapy in Patients With Inoperable Non-Small Cell Lung Cancer.

Sponsor: Maastricht Radiation Oncology

Conditions Non-Small-Cell Lung Carcinoma

Interventions dose escalation (radiotherapy treatment schedule)

Updated 5 times since 2017 Last updated: Jun 29, 2009 Started: Dec 31, 2001 Primary completion: Dec 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Non-Small-Cell Lung Carcinoma and is currently completed. Maastricht Radiation Oncology leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Dec 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Maastricht Radiation Oncology

Data source: Maastricht Radiation Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Heerlen, Netherlands